ClinicalTrials.gg
CompletedNCT02151110Updated Feb 15, 2019Results posted

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

A Phase 1 interventional study of MEDI4920 3 mg and MEDI4920 10 mg in Healthy Volunteer, sponsored by MedImmune LLC. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-15.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Study summary

Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Male
  • Healthy Female of non child bearing potential
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy as determined by a responsible study physician based on medical evaluation
  • Body weight 40 to 100 kg
  • 19.0 to 30.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • History of allergy or sensitivity to Shellfish or protein based antigens
  • previous immunization with KLH
  • previous splenectomy
  • History of diagnosed or suspected thromboembolic event or coagulation disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
59 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.

    Other: Placebo

  • Experimental
    MEDI4920 3 mg

    Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.

    Biological: MEDI4920 3 mg

  • Experimental
    MEDI4920 10 mg

    Participants received single IV dose of MEDI4920 10 mg infused on Day 1.

    Biological: MEDI4920 10 mg

  • Experimental
    MEDI4920 30 mg

    Participants received single IV dose of MEDI4920 30 mg infused on Day 1.

    Biological: MEDI4920 30 mg

  • Experimental
    MEDI4920 100 mg

    Participants received single IV dose of MEDI4920 100 mg infused on Day 1.

    Biological: MEDI4920 100 mg

  • Experimental
    MEDI4920 300 mg

    Participants received single IV dose of MEDI4920 300 mg infused on Day 1.

    Biological: MEDI4920 300 mg

  • Experimental
    MEDI4920 1000 mg

    Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.

    Biological: MEDI4920 1000 mg

  • Experimental
    MEDI4920 3000 mg

    Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.

    Biological: MEDI4920 3000 mg

Interventions

  • BiologicalMEDI4920 3 mg

    Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.

  • BiologicalMEDI4920 10 mg

    Participants received single IV dose of MEDI4920 10 mg infused on Day 1.

  • BiologicalMEDI4920 30 mg

    Participants received single IV dose of MEDI4920 30 mg infused on Day 1.

  • BiologicalMEDI4920 100 mg

    Participants received single IV dose of MEDI4920 100 mg infused on Day 1.

  • BiologicalMEDI4920 300 mg

    Participants received single IV dose of MEDI4920 300 mg infused on Day 1.

  • Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.

  • Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.

  • OtherPlacebo

    Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug. A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.

    Time frame: The start of study drug administration (Day 1) to the follow-up period (Day 113) or early discontinuation visit

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of MEDI4920

    The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  2. Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920

    The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920

    The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  4. Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920

    The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose. The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  5. Terminal Elimination Half Life (t1/2) of MEDI4920

    The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  6. Systemic Clearance (CL) of MEDI4920

    The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  7. Volume of Distribution at Steady-state (Vss) of MEDI4920

    The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  8. Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920

    The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

    Time frame: Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first

  9. Percentage of Participants Positive for Anti-drug Antibodies (ADA)

    Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920. The incidence of positive serum antibodies to MEDI4920 are presented.

    Time frame: Baseline (pre-infusion on Day 1) and post-baseline Days 15, 29, 57, and 113 or early discontinuation visit, whichever occurred first

  10. T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration

    The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH). The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research. TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization. The primary time point for the analysis of the TDAR to KLH was Day 43. The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.

    Time frame: Day 43

07

Results

Posted Feb 15, 2019

Participant flow

Healthy adult male and female participants were recruited in a blinded manner. The study was conducted at one site in the United Kingdom.

Participant flow — Overall Study
MilestonePlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Started122288888
Completed122288885
Not completed00000003
Withdrew: Withdrawal by subject00000001
Withdrew: Lost to follow-up00000002

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening situation (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly or birth defect in the offspring of a participant who received the study drug. A TEAE is defined as the event with onset after the start of infusion (Day 1) to Day 113 or early discontinuation visit inclusive. The AEs were summarized using Medical Dictionary for Regulatory Activities version 19.0.

Time frame:
The start of study drug administration (Day 1) to the follow-up period (Day 113) or early discontinuation visit
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
TEAEs101158357
TESAEs10000000
SecondaryMaximum Observed Plasma Concentration (Cmax) of MEDI4920

The maximum observed plasma concentration (Cmax) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · microgram per milliliter (µg/mL)
Maximum Observed Plasma Concentration (Cmax) of MEDI4920
microgram per milliliter (µg/mL)MEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Maximum Observed Plasma Concentration (Cmax) of MEDI49201.00 ± NA4.46 ± NA7.97 ± 0.87323.6 ± 2.7685.6 ± 17.6289 ± 58.1960 ± 126
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920

The area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-last) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · microgram*day per milliliter (µg*d/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI4920
microgram*day per milliliter (µg*d/mL)MEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-last) of MEDI49203.64 ± NA19.3 ± NA53.4 ± 10.9151 ± 20.2581 ± 38.32090 ± 3946640 ± 553
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920

The area under the plasma concentration-time curve from time zero to infinity (AUC 0-inf) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · microgram*day per milliliter (µg*d/mL)
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI4920
microgram*day per milliliter (µg*d/mL)MEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MEDI49204.60 ± NA20.5 ± NA54.8 ± 11.0152 ± 20.2583 ± 37.82090 ± 3946640 ± 547
SecondaryDose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920

The AUC (0-infinity)/D is the area under concentration-time curve extrapolated to infinity postdose normalized by MEDI4920 dose. The AUC (0-infinity)/D was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · µg*d/mL/mg
Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI4920
µg*d/mL/mgMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Dose-normalized AUC0-inf (AUC0-infinity/D) of MEDI49201.53 ± NA2.05 ± NA1.83 ± 0.3661.52 ± 0.2021.94 ± 0.1262.09 ± 0.3942.21 ± 0.182
SecondaryTerminal Elimination Half Life (t1/2) of MEDI4920

The terminal elimination half-life (t1/2) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · Day(s)
Terminal Elimination Half Life (t1/2) of MEDI4920
Day(s)MEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Terminal Elimination Half Life (t1/2) of MEDI49204.41 ± NA5.35 ± NA5.31 ± 2.305.49 ± 1.598.86 ± 1.609.68 ± 1.2510.1 ± 1.87
SecondarySystemic Clearance (CL) of MEDI4920

The systemic clearance (CL) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · milliliter per day (mL/day)
Systemic Clearance (CL) of MEDI4920
milliliter per day (mL/day)MEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Systemic Clearance (CL) of MEDI4920661 ± NA487 ± NA564 ± 96.8668 ± 90.4517 ± 33.5494 ± 102454 ± 37.9
SecondaryVolume of Distribution at Steady-state (Vss) of MEDI4920

The volume of distribution at steady-state (Vss) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · milliliter (mL)
Volume of Distribution at Steady-state (Vss) of MEDI4920
milliliter (mL)MEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Volume of Distribution at Steady-state (Vss) of MEDI49203980 ± NA3290 ± NA4280 ± 6845560 ± 8065180 ± 8115450 ± 11504900 ± 715
SecondaryVolume of Distribution Based on Terminal Phase (Vz) of MEDI4920

The volume of distribution based on terminal phase (Vz) was estimated based on the plasma concentrations of MEDI4920. Standard deviation was calculated only if number of participants were more than or equal to 3.

Time frame:
Pre-infusion, at the middle of the infusion, post-infusion (5 minutes, and 2, 6, and 12 hours) on Day 1; Days 2, 3, 5, 8, 15, 22, 29, 43, 57, 85, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Mean · milliliter (mL)
Volume of Distribution Based on Terminal Phase (Vz) of MEDI4920
milliliter (mL)MEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Volume of Distribution Based on Terminal Phase (Vz) of MEDI49204130 ± NA3760 ± NA4080 ± 10905230 ± 13606590 ± 11606880 ± 15206600 ± 1190
SecondaryPercentage of Participants Positive for Anti-drug Antibodies (ADA)

Plasma samples were collected for assessment of anti-drug antibodies (ADA) against MEDI4920. The incidence of positive serum antibodies to MEDI4920 are presented.

Time frame:
Baseline (pre-infusion on Day 1) and post-baseline Days 15, 29, 57, and 113 or early discontinuation visit, whichever occurred first
Reported as:
Number · Percentage of participants
Percentage of Participants Positive for Anti-drug Antibodies (ADA)
Percentage of participantsPlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Baseline ADA positive16.70000000
Post-baseline ADA positive8.35010010087.537.537.512.5
SecondaryT-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration

The T-cell dependent antibody response (TDAR) assay measures the immune response (ie, antibody production) to an introduced antigen, keyhole limpet hemocyanin (KLH). The KLH is a potent immunostimulating protein with an extensive history of safe and effective use in vaccine development and immunological research. TDAR was evaluated by measuring anti-KLH IgG titers at a time point consistent with the expected timing for antibody responses following immunization. The primary time point for the analysis of the TDAR to KLH was Day 43. The data was presented for geometric mean ratio (MEDI4920/placebo) estimated from the dose response model.

Time frame:
Day 43
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) Concentration
nanogram per milliliter (ng/mL)PlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
T-cell Dependent Antibody Response (TDAR) Measured by Anti-keyhole Limpet Hemocyanin Immunoglobulin G (Anti-KLH IgG) ConcentrationNA (NA to NA)0.99 (0.96 to 1.01)0.96 (0.89 to 1.03)0.88 (0.72 to 1.08)0.68 (0.41 to 1.14)0.42 (0.18 to 0.97)0.22 (0.10 to 0.47)0.14 (0.06 to 0.32)

Adverse events

Collected over Adverse events were collected from time of signature of informed consent, throughout the treatment period, and the follow-up period (through Day 113 or early discontinuation visit).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/12 (0%)1/12 (8.3%)10/12 (83.3%)
MEDI4920 3 mg0/2 (0%)0/2 (0%)1/2 (50%)
MEDI4920 10 mg0/2 (0%)0/2 (0%)1/2 (50%)
MEDI4920 30 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
MEDI4920 100 mg0/8 (0%)0/8 (0%)8/8 (100%)
MEDI4920 300 mg0/8 (0%)0/8 (0%)3/8 (37.5%)
MEDI4920 1000 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
MEDI4920 3000 mg0/8 (0%)0/8 (0%)7/8 (87.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
Tibia fractureInjury, poisoning and procedural complications1/120/20/20/80/80/80/80/8
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mg
NasopharyngitisInfections and infestations1/120/21/20/85/81/81/82/8
BlepharitisEye disorders0/121/20/20/80/80/80/80/8
DiarrhoeaGastrointestinal disorders0/120/21/20/80/81/82/81/8
VomitingGastrointestinal disorders1/120/21/20/80/81/80/80/8
HordeolumInfections and infestations0/121/20/20/80/80/80/80/8
HeadacheNervous system disorders4/120/21/22/80/81/81/83/8
Memory impairmentNervous system disorders0/121/20/20/80/80/80/80/8
Nasal congestionRespiratory, thoracic and mediastinal disorders1/120/21/20/81/80/80/81/8
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/120/21/21/81/80/80/81/8
Ear discomfortEar and labyrinth disorders0/120/20/20/82/80/80/80/8

Baseline characteristics

As-treated population included all participants who received any study drug. Two participants were erroneously randomized to MEDI4920 10 mg group due to the IXRS system not being opened for start of MEDI4920 30 mg group. However, these participants received the 30 mg dose.

Age, Continuous
Age, Continuous(Years)PlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mgTOTAL
Mean33.3 ± 8.927.5 ± 4.926.0 ± 1.427.8 ± 12.328.1 ± 10.138.4 ± 9.333.3 ± 9.232.0 ± 9.831.8 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI4920 3 mgMEDI4920 10 mgMEDI4920 30 mgMEDI4920 100 mgMEDI4920 300 mgMEDI4920 1000 mgMEDI4920 3000 mgTOTAL
Female000000000
Male12228888856
08

Study locations

1 site
  • Research Site
    Leeds, LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2014 to primary completion in May 2016, 23 months.

Results were first posted in Feb 2019, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2014
First posted
May 30, 2014
StartActual
May 27, 2014
Primary completionActual
May 9, 2016
CompletionActual
May 9, 2016
Results first posted
Feb 15, 2019
Last update
Feb 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02151110
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
May 30, 2014
Start date
May 27, 2014
Primary completion
May 9, 2016
Completion
May 9, 2016
Results posted
Feb 15, 2019
Last update
Feb 15, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazodalibep

Start the discussion